var data={"title":"Noncirrhotic portal hypertension","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Noncirrhotic portal hypertension</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/contributors\" class=\"contributor contributor_credentials\">Juan Carlos Garcia-Pag&aacute;n, MD, PhD</a></dd><dd><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/contributors\" class=\"contributor contributor_credentials\">Jason Chang Pik Eu, MBBS, MRCP</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/contributors\" class=\"contributor contributor_credentials\">Sanjiv Chopra, MD, MACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/contributors\" class=\"contributor contributor_credentials\">Kristen M Robson, MD, MBA, FACG</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jan 11, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Portal hypertension is defined by a pathologic increase in the pressure of the portal venous system. Cirrhosis is the most common cause of portal hypertension, but it can also be present in the absence of cirrhosis, a condition referred to as &quot;noncirrhotic portal hypertension.&quot;</p><p>This topic will review the differential diagnosis of noncirrhotic portal hypertension and will discuss in detail two of the disorders associated with noncirrhotic portal hypertension, schistosomiasis, and idiopathic noncirrhotic portal hypertension (INCPH). Other causes of noncirrhotic portal hypertension are discussed elsewhere.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=acute-portal-vein-thrombosis-in-adults-clinical-manifestations-diagnosis-and-management\" class=\"medical medical_review\">&quot;Acute portal vein thrombosis in adults: Clinical manifestations, diagnosis, and management&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=chronic-portal-vein-thrombosis-in-adults-clinical-manifestations-diagnosis-and-management\" class=\"medical medical_review\">&quot;Chronic portal vein thrombosis in adults: Clinical manifestations, diagnosis, and management&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-prognosis-of-primary-biliary-cholangitis-primary-biliary-cirrhosis\" class=\"medical medical_review\">&quot;Clinical manifestations, diagnosis, and prognosis of primary biliary cholangitis (primary biliary cirrhosis)&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=primary-sclerosing-cholangitis-in-adults-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Primary sclerosing cholangitis in adults: Clinical manifestations and diagnosis&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=budd-chiari-syndrome-epidemiology-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Budd-Chiari syndrome: Epidemiology, clinical manifestations, and diagnosis&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=diagnosis-of-hepatic-sinusoidal-obstruction-syndrome-veno-occlusive-disease-following-hematopoietic-cell-transplantation\" class=\"medical medical_review\">&quot;Diagnosis of hepatic sinusoidal obstruction syndrome (veno-occlusive disease) following hematopoietic cell transplantation&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=extrarenal-manifestations-of-autosomal-dominant-polycystic-kidney-disease#H9\" class=\"medical medical_review\">&quot;Extrarenal manifestations of autosomal dominant polycystic kidney disease&quot;, section on 'Hepatic cysts'</a> and <a href=\"topic.htm?path=diagnosis-and-management-of-cystic-lesions-of-the-liver#H22\" class=\"medical medical_review\">&quot;Diagnosis and management of cystic lesions of the liver&quot;, section on 'Polycystic liver disease'</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=acute-fatty-liver-of-pregnancy\" class=\"medical medical_review\">&quot;Acute fatty liver of pregnancy&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=hepatotoxicity-associated-with-chronic-low-dose-methotrexate-for-nonmalignant-disease\" class=\"medical medical_review\">&quot;Hepatotoxicity associated with chronic low-dose methotrexate for nonmalignant disease&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=drug-induced-liver-injury\" class=\"medical medical_review\">&quot;Drug-induced liver injury&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=amiodarone-monitoring-and-management-of-side-effects#H11\" class=\"medical medical_review\">&quot;Amiodarone: Monitoring and management of side effects&quot;, section on 'Hepatotoxicity'</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=hepatic-granulomas\" class=\"medical medical_review\">&quot;Hepatic granulomas&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=constrictive-pericarditis\" class=\"medical medical_review\">&quot;Constrictive pericarditis&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=definition-and-classification-of-the-cardiomyopathies#H8\" class=\"medical medical_review\">&quot;Definition and classification of the cardiomyopathies&quot;, section on 'Restrictive cardiomyopathy'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H64319454\"><span class=\"h1\">ETIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Disorders associated with noncirrhotic portal hypertension can be categorized based on their site of involvement into prehepatic, intrahepatic or posthepatic causes. Intrahepatic causes can be further subcategorized as presinusoidal, sinusoidal, and postsinusoidal (<a href=\"image.htm?imageKey=GAST%2F76516\" class=\"graphic graphic_table graphicRef76516 \">table 1</a>). In some cases, a given disorder may affect multiple sites (eg, vinyl chloride toxicity, Gaucher disease, alcoholic liver disease).</p><p class=\"headingAnchor\" id=\"H64319853\"><span class=\"h2\">Prehepatic and posthepatic causes</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Prehepatic and posthepatic causes of portal hypertension are disorders causing disruption of the vascular system leading to increased pressure in the portal venous system, without direct involvement of the liver parenchyma. Prehepatic causes include portal or splenic vein thrombosis, splanchnic arteriovenous fistulas, and splenomegaly (eg, due to myeloproliferative disease or Gaucher disease). </p><p>Posthepatic causes include obstruction of the hepatic veins or the inferior vena cava (eg, from Budd-Chiari syndrome) and cardiac diseases (eg, constrictive pericarditis and restrictive cardiomyopathy).</p><p class=\"headingAnchor\" id=\"H64319860\"><span class=\"h2\">Intrahepatic causes</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The intrahepatic causes of noncirrhotic portal hypertension may be presinusoidal, sinusoidal, or postsinusoidal.</p><p class=\"headingAnchor\" id=\"H64319867\"><span class=\"h3\">Presinusoidal causes</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Presinusoidal causes of noncirrhotic portal hypertension include [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/1\" class=\"abstract_t\">1</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Developmental abnormalities (eg, adult polycystic liver disease, congenital hepatic fibrosis, arteriovenous fistulas)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Biliary diseases (eg, biliary cirrhosis, autoimmune cholangiopathy, primary sclerosing cholangitis, toxic biliary injury from vinyl chloride)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Neoplastic occlusion of the intrahepatic portal vein (eg, due to lymphoma, epithelioid hemangioendothelioma, epithelial malignancies, chronic lymphocytic leukemia)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Granulomatous liver lesions (eg, schistosomiasis, <a href=\"topic.htm?path=mineral-oil-drug-information\" class=\"drug drug_general\">mineral oil</a> granuloma, sarcoidosis)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Idiopathic noncirrhotic portal hypertension (INCPH)</p><p/><p class=\"headingAnchor\" id=\"H64319886\"><span class=\"h3\">Sinusoidal causes</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Sinusoidal causes of noncirrhotic portal hypertension include [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/1\" class=\"abstract_t\">1</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Fibrosis of the space of Disse, which may be metabolic (eg, nonalcoholic fatty liver disease, Zellweger syndrome), inflammatory (viral hepatitis, chronic Q fever, prior cytomegalovirus, schistosomiasis), or induced by drugs or toxins (eg, <a href=\"topic.htm?path=amiodarone-drug-information\" class=\"drug drug_general\">amiodarone</a>, <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a>, alcohol, vinyl chloride, copper) [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/2-5\" class=\"abstract_t\">2-5</a>]</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Amyloid or light-chain deposition in the space of Disse</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Defenestration of the sinusoidal lining in early alcoholic liver disease</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Sinusoidal destruction or collapse in the setting of acute hepatic injury</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Infiltrative diseases such as mastocytosis, Gaucher disease, and agnogenic myeloid metaplasia</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Compression of sinusoids by markedly hypertrophied hepatocytes, which may be seen with microvesicular steatosis</p><p/><p class=\"headingAnchor\" id=\"H64319893\"><span class=\"h3\">Postsinusoidal causes</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Postsinusoidal causes of noncirrhotic portal hypertension include [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/1\" class=\"abstract_t\">1</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Sinusoidal obstruction syndrome (venoocclusive disease)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Budd-Chiari syndrome</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Phlebosclerosis of hepatic veins (eg, due to alcoholic liver disease, chronic radiation injury, hypervitaminosis A)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Primary vascular malignancies (eg, epithelioid hemangioendothelioma, angiosarcoma)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Granulomatous phlebitis (eg, from sarcoidosis, <em>Mycobacterium avium</em> or <em>M. intracellulare</em> infection)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Lipogranulomas (eg, <a href=\"topic.htm?path=mineral-oil-drug-information\" class=\"drug drug_general\">mineral oil</a> granuloma)</p><p/><p class=\"headingAnchor\" id=\"H64323358\"><span class=\"h1\">SCHISTOSOMIASIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Schistosomiasis is one of the most common causes of noncirrhotic portal hypertension worldwide [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/6\" class=\"abstract_t\">6</a>]. Of the three main Schistosoma species, <em>S. japonicum</em> and <em>S. mansoni</em> are known to cause liver disease. <em>S. hematobium</em> affects mainly the urinary tract, although at advanced stages the liver can develop portal fibrosis. The acute stage of schistosomiasis mimics acute bacterial infection and is accompanied by marked eosinophilia. Chronic hepatic schistosomiasis is characterized by features of portal hypertension: esophageal varices, hepatomegaly, and splenomegaly with hypersplenism. The diagnosis of schistosomiasis can be made by the detection of schistosomal ova in the stool. Management includes treating underlying parasitic infection and preventing or treating the consequences of portal hypertension. (See <a href=\"topic.htm?path=epidemiology-pathogenesis-and-clinical-manifestations-of-schistosomiasis\" class=\"medical medical_review\">&quot;Epidemiology, pathogenesis, and clinical manifestations of schistosomiasis&quot;</a> and <a href=\"topic.htm?path=diagnosis-of-schistosomiasis\" class=\"medical medical_review\">&quot;Diagnosis of schistosomiasis&quot;</a> and <a href=\"topic.htm?path=treatment-and-prevention-of-schistosomiasis\" class=\"medical medical_review\">&quot;Treatment and prevention of schistosomiasis&quot;</a>.)</p><p><em>S. japonicum</em> is distributed widely throughout the world, predominantly in Asia. <em>S. mansoni</em> is endemic in Egypt, Africa, the Middle East, and South America. Two other species (<em>S. mekongi</em> and <em>S. intercalatum</em>) also cause hepatic infections in endemic areas in Southeast Asia and Western Africa, respectively.</p><p class=\"headingAnchor\" id=\"H64323364\"><span class=\"h2\">Pathophysiology</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The infection occurs when the schistosomal cercariae enter the body through the skin. Adult worms eventually find their way to inhabit tributaries of the inferior (<em>S. mansoni</em>) or superior (<em>S. japonicum</em>) mesenteric veins, where they produce hundreds to thousands eggs per day for several years before the end of their lifespan (<a href=\"image.htm?imageKey=ID%2F90007\" class=\"graphic graphic_figure graphicRef90007 \">figure 1</a>). Some of these eggs pass through the intestinal mucosa and are excreted in the urine or feces to continue their life cycle. Others flow into the portal vein tributaries and become trapped in the terminal portal venules, where they induce chronic inflammation that is subsequently followed by marked fibrosis. <em>S. japonicum</em> is capable of producing far more eggs than <em>S. mansoni</em> and thus causes more severe liver disease [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/7,8\" class=\"abstract_t\">7,8</a>]. (See <a href=\"topic.htm?path=epidemiology-pathogenesis-and-clinical-manifestations-of-schistosomiasis\" class=\"medical medical_review\">&quot;Epidemiology, pathogenesis, and clinical manifestations of schistosomiasis&quot;</a>.)</p><p>In the early stages of infection, the portal resistance is mainly presinusoidal. However, as the fibrotic changes in the portal tracts progress, lobular distortion at the sinusoidal level occurs. This results in an increase in resistance to portal venous flow, as evidenced by an increased wedged hepatic venous pressure in advanced cases [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/9\" class=\"abstract_t\">9</a>]. Hemodynamic studies in patients with hepatic schistosomiasis have demonstrated a hyperdynamic systemic and splanchnic circulation with normal hepatic venous pressure gradient and total hepatic blood flow [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/7,10,11\" class=\"abstract_t\">7,10,11</a>]. (See <a href=\"topic.htm?path=portal-hypertension-in-adults#H72827684\" class=\"medical medical_review\">&quot;Portal hypertension in adults&quot;, section on 'Hepatic venous pressure gradient'</a>.)</p><p class=\"headingAnchor\" id=\"H64323370\"><span class=\"h2\">Clinical features</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Chronic hepatic schistosomiasis is characterized by features of portal hypertension: esophageal varices, hepatomegaly, and splenomegaly with hypersplenism. In children, chronic infection is associated with growth retardation. Many patients with mild fibrosis are asymptomatic during the earlier phases of their disease. (See <a href=\"topic.htm?path=epidemiology-pathogenesis-and-clinical-manifestations-of-schistosomiasis#H6283817\" class=\"medical medical_review\">&quot;Epidemiology, pathogenesis, and clinical manifestations of schistosomiasis&quot;, section on 'Hepatosplenic schistosomiasis'</a>.)</p><p>Underlying hepatic function remains preserved in hepatic schistosomiasis, and hepatic encephalopathy, ascites, and liver failure are uncommon. Patients with hepatic schistosomiasis tolerate episodes of acute variceal bleeding well compared with patients with cirrhosis because of their preserved liver function. In advanced cases, hepatic decompensation may develop, with hypoalbuminemia and chronic ascites. However, this tends to occur in patients with coexisting liver disease such as chronic viral hepatitis B or C infection or alcoholic liver disease. These coexisting liver diseases have been found to aggravate the course of hepatic schistosomiasis, changing its natural history [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/12-14\" class=\"abstract_t\">12-14</a>]. Extrahepatic manifestations, such as pneumonia and pulmonary hypertension, have been described in <em>S. mansoni</em> infection [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/15\" class=\"abstract_t\">15</a>]. (See <a href=\"topic.htm?path=epidemiology-pathogenesis-and-clinical-manifestations-of-schistosomiasis#H6283817\" class=\"medical medical_review\">&quot;Epidemiology, pathogenesis, and clinical manifestations of schistosomiasis&quot;, section on 'Hepatosplenic schistosomiasis'</a>.)</p><p class=\"headingAnchor\" id=\"H64323394\"><span class=\"h2\">Diagnosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of schistosomiasis can be made by the detection of schistosomal eggs in the stool (<a href=\"image.htm?imageKey=ID%2F58729\" class=\"graphic graphic_picture graphicRef58729 \">picture 1</a>). As an alternative, it can be demonstrated in biopsies of the rectal mucosa (<a href=\"image.htm?imageKey=NEPH%2F88449\" class=\"graphic graphic_picture graphicRef88449 \">picture 2</a>) or the liver. Because the worms concentrate more densely in the distal colon, the rectal mucosa has a heavy load of schistosomal eggs. The diagnosis can also be made using various immunologic assays [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/16\" class=\"abstract_t\">16</a>]. (See <a href=\"topic.htm?path=diagnosis-of-schistosomiasis\" class=\"medical medical_review\">&quot;Diagnosis of schistosomiasis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H64323400\"><span class=\"h2\">Management</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=praziquantel-drug-information\" class=\"drug drug_general\">Praziquantel</a> and oxamniquine are active against all forms of human schistosomiasis and are effective in eradicating the worms in the acute stage of the disease. Cure rates vary from 60 to 90 percent for <em>S. mansoni</em> and 60 to 80 percent for <em>S. japonicum</em> [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/17,18\" class=\"abstract_t\">17,18</a>]. Even if treatment does not kill all the worms, it will result in a sharp reduction in egg laying. In patients with chronic schistosomiasis, the worms no longer lay eggs and the patient may not require any specific antihelminthic treatment. (See <a href=\"topic.htm?path=treatment-and-prevention-of-schistosomiasis#H13464830\" class=\"medical medical_review\">&quot;Treatment and prevention of schistosomiasis&quot;, section on 'Treatment'</a>.)</p><p>In addition to treating the underlying parasitic infection, management should be aimed at preventing or treating the consequences of portal hypertension (predominantly variceal bleeding). Only a few studies have described treatment options in these patients. As a result, patients are typically managed similarly to patients with varices in the setting of cirrhosis [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/19\" class=\"abstract_t\">19</a>]. (See <a href=\"topic.htm?path=cirrhosis-in-adults-overview-of-complications-general-management-and-prognosis#H60385021\" class=\"medical medical_review\">&quot;Cirrhosis in adults: Overview of complications, general management, and prognosis&quot;, section on 'Complications of portal hypertension'</a>.)</p><p>Treatment for acute variceal bleeding includes early pharmacologic treatment with vasoactive drugs, early endoscopic control of bleeding, careful blood product replacement, and prophylactic antibiotics. (See <a href=\"topic.htm?path=general-principles-of-the-management-of-variceal-hemorrhage\" class=\"medical medical_review\">&quot;General principles of the management of variceal hemorrhage&quot;</a>.)</p><p>Primary and secondary prevention of variceal bleeding includes the use of nonselective beta blockers and endoscopic variceal ligation. (See <a href=\"#H18\" class=\"local\">'Management'</a> below and <a href=\"topic.htm?path=primary-and-pre-primary-prophylaxis-against-variceal-hemorrhage-in-patients-with-cirrhosis\" class=\"medical medical_review\">&quot;Primary and pre-primary prophylaxis against variceal hemorrhage in patients with cirrhosis&quot;</a> and <a href=\"topic.htm?path=prevention-of-recurrent-variceal-hemorrhage-in-patients-with-cirrhosis\" class=\"medical medical_review\">&quot;Prevention of recurrent variceal hemorrhage in patients with cirrhosis&quot;</a>.)</p><p>Surgery has been used for patients with noncirrhotic portal hypertension from schistosomiasis who have recurrent variceal bleeding despite medical and endoscopic treatment [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/20\" class=\"abstract_t\">20</a>]. Surgical options included splenectomy with esophagogastric devascularization or selective shunts (eg, distal splenorenal shunts) [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/21,22\" class=\"abstract_t\">21,22</a>]. In a trial of 47 patients with schistosomiasis and a history of variceal bleeding, patients treated with splenectomy and esophageal devascularization had a lower rate of recurrent bleeding compared with patients treated with endoscopic sclerotherapy (9 versus 36 percent) [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/22\" class=\"abstract_t\">22</a>]. Nonselective shunts (eg, proximal splenorenal shunts) are not recommended because they are associated with high rates of hepatic encephalopathy, hemolysis, and death [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/23\" class=\"abstract_t\">23</a>]. Transjugular intrahepatic portosystemic shunt placement may be an alternative to surgery, but also puts patients at risk for hepatic encephalopathy [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/21\" class=\"abstract_t\">21</a>]. (See <a href=\"topic.htm?path=role-of-transjugular-intrahepatic-portosystemic-shunts-in-the-treatment-of-variceal-bleeding\" class=\"medical medical_review\">&quot;Role of transjugular intrahepatic portosystemic shunts in the treatment of variceal bleeding&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">IDIOPATHIC NONCIRRHOTIC PORTAL HYPERTENSION (INCLUDING NODULAR REGENERATIVE HYPERPLASIA)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Idiopathic noncirrhotic portal hypertension (INCPH) has been referred to by several different names, including nodular regenerative hyperplasia. It is characterized by portal hypertension in the absence of liver cirrhosis, with histologic features of dense portal fibrosis, marked phlebosclerosis, and dilated sinusoids. It typically has a more benign course than portal hypertension that develops in the setting of cirrhosis, though patients may present with complications such as variceal bleeding. The diagnosis is made by ruling out other causes of portal hypertension. Management is primarily aimed at decreasing the risk of variceal bleeding (eg, with beta blockers or variceal banding).</p><p class=\"headingAnchor\" id=\"H64320103\"><span class=\"h2\">Terminology</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Noncirrhotic portal hypertension without an identifiable cause has been referred to by various names. We, as well as others, prefer to use the term idiopathic noncirrhotic portal hypertension (INCPH) [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/1,24\" class=\"abstract_t\">1,24</a>].</p><p>Other terms that have been used for idiopathic noncirrhotic portal hypertension include [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/25-32\" class=\"abstract_t\">25-32</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Nodular regenerative hyperplasia</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Noncirrhotic portal fibrosis</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Idiopathic portal hypertension</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hepatoportal sclerosis</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Incomplete septal cirrhosis</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Obliterative portal venopathy</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Benign intrahepatic portal hypertension</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Idiopathic presinusoidal portal hypertension</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Partial nodular transformation</p><p/><p>In the past, it was thought that these entities represented different disorders. However, the clinicopathologic features are sufficiently similar that they are now considered to be the same disease. While differences in epidemiology, hepatic pressure gradients, and proposed etiology have been described in reports from different geographical areas, the differences likely reflect the varied spectrum of this disease and not separate disease entities [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/1\" class=\"abstract_t\">1</a>]. (See <a href=\"#H15\" class=\"local\">'Liver pathology'</a> below.)</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Epidemiology</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The incidence of idiopathic noncirrhotic portal hypertension varies worldwide. Studies from the 1980s and 1990s suggested it accounts for approximately 23 percent of cases of portal hypertension in India [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/33,34\" class=\"abstract_t\">33,34</a>], whereas older studies suggested it accounts for 3 to 5 percent of cases of portal hypertension in Western countries [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/35\" class=\"abstract_t\">35</a>]. Among Western patients, it is thought to account for 14 to 27 percent of cases of noncirrhotic portal hypertension [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/36-38\" class=\"abstract_t\">36-38</a>]. However, over time, fewer cases have been reported, suggesting that the incidence may now be much lower [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/1,34\" class=\"abstract_t\">1,34</a>].</p><p>In Eastern countries, the disease is often encountered in patients who are socioeconomically disadvantaged [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/39\" class=\"abstract_t\">39</a>]. Slight differences in the sex and age distribution have been reported from different countries [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/40,41\" class=\"abstract_t\">40,41</a>]. The reason for this is not clear, but differences in socioeconomic status, living conditions, pathogen exposure, average life span, and ethnicity may play a role. In Japan, the incidence of idiopathic noncirrhotic portal hypertension has declined in recent decades, possibly because of improvements in hygiene and living standards [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/41\" class=\"abstract_t\">41</a>].</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Pathophysiology</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The etiology of idiopathic noncirrhotic portal hypertension is unknown. However, several pathophysiologic mechanisms are believed to be involved, including chronic or recurrent infections, exposures to drugs or toxins, immunologic disorders, genetic disorders, and hypercoagulability. A large number of disorders, medications, and toxins have been associated with idiopathic noncirrhotic portal hypertension (<a href=\"image.htm?imageKey=GAST%2F50663\" class=\"graphic graphic_table graphicRef50663 \">table 2</a>).</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Chronic or recurrent infections &ndash; Repeated episodes of umbilical sepsis, bacterial infections, and diarrhea in early childhood (all relatively common in socioeconomically disadvantaged populations) are believed to lead to portal pyemia and pylephlebitis, which may subsequently cause vascular endothelial injury, microthrombosis, sclerosis, and obstruction of small- and medium-sized portal vein radicals. This may subsequently lead to the development of idiopathic noncirrhotic portal hypertension in early adulthood [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/42\" class=\"abstract_t\">42</a>]. Supporting this hypothesis, animal studies involving repeated injections of <em>Escherichia coli</em> into the portal system of rabbits resulted in the development of noncirrhotic portal fibrosis [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/43\" class=\"abstract_t\">43</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Drugs and toxins &ndash; Drugs and toxins may induce fibrosis in the space of Disse, leading to idiopathic noncirrhotic portal hypertension [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/1\" class=\"abstract_t\">1</a>]. Drugs associated with idiopathic noncirrhotic portal hypertension include <a href=\"topic.htm?path=azathioprine-drug-information\" class=\"drug drug_general\">azathioprine</a> and several cytotoxic drugs.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Human immunodeficiency virus (HIV) infection &ndash; There have been consistent reports of patients with HIV infection who develop variceal bleeding due to underlying noncirrhotic portal hypertension [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/44-49\" class=\"abstract_t\">44-49</a>]. The pathogenesis is thought to be related to the effect of highly active antiretroviral treatment (particularly long-term exposure to <a href=\"topic.htm?path=didanosine-drug-information\" class=\"drug drug_general\">didanosine</a>) on the microvasculature of the liver or the direct effect of the HIV itself [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/46,50\" class=\"abstract_t\">46,50</a>]. The discontinuation of didanosine has been reported in some studies to reduce the progression of idiopathic noncirrhotic portal hypertension [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/51,52\" class=\"abstract_t\">51,52</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Altered immune response &ndash; Several alterations in the immunologic response have been described in patients with idiopathic noncirrhotic portal hypertension [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/53,54\" class=\"abstract_t\">53,54</a>]. In addition, different autoimmune diseases are frequently associated with idiopathic noncirrhotic portal hypertension (<a href=\"image.htm?imageKey=GAST%2F50663\" class=\"graphic graphic_table graphicRef50663 \">table 2</a>) [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/55-57\" class=\"abstract_t\">55-57</a>]. Anti-DNA antibodies are demonstrable in more than 65 percent of Japanese women with idiopathic noncirrhotic portal hypertension [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/55\" class=\"abstract_t\">55</a>]. Studies have also reported the presence of idiopathic noncirrhotic portal hypertension and portal systemic collaterals in some patients with severe primary antibody deficiencies [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/58\" class=\"abstract_t\">58</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Genetic predisposition &ndash;Few studies have shown potential genetic mechanisms involved in the development of idiopathic noncirrhotic portal hypertension. In a study of eight patients with early onset noncirrhotic portal hypertension, a shared mutation in DGUOK, a deoxyguanosine kinase required for mitochondrial DNA replication, was identified [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/59\" class=\"abstract_t\">59</a>]. Familial aggregation of idiopathic noncirrhotic portal hypertension and a high frequency of HLA-DR3 have been observed, suggesting a potential genetic pathogenesis [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/60\" class=\"abstract_t\">60</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Hypercoagulability &ndash; Some studies have suggested an association of idiopathic noncirrhotic portal hypertension with a hypercoagulable state. A study of idiopathic noncirrhotic portal hypertension in 28 Western patients found evidence of various prothrombotic disorders in 50 percent of patients [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/61\" class=\"abstract_t\">61</a>]. Over the course of follow-up, 13 patients developed portal vein thrombosis within a median of 7.6 years (range 1 to 21 years). The authors advocated anticoagulant therapy in patients with idiopathic noncirrhotic portal hypertension found to have a prothrombotic disorder. Similarly, a report from Turkey described extrahepatic portal vein thrombosis in 7 of 34 (20 percent) patients with idiopathic noncirrhotic portal hypertension over a five-year follow-up period [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/62\" class=\"abstract_t\">62</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Miscellaneous &ndash; Preliminary observations have described a role for endothelin-1, nitric oxide, and connective tissue growth factor in development of idiopathic noncirrhotic portal hypertension [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/63-67\" class=\"abstract_t\">63-67</a>].</p><p/><p>It has been proposed that a central event in the development of idiopathic noncirrhotic portal hypertension is portal venopathy caused by thrombosis or obliteration due to hypercoagulability, endothelial injury, or autoimmune injury (from immune complex deposition, autoantibodies, or activated T cells) [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/36,68-72\" class=\"abstract_t\">36,68-72</a>].</p><p>A vascular cause of idiopathic noncirrhotic portal hypertension is supported by experimental studies in animals and histologic findings in humans. Blockage of the portal veins decreases blood flow to the liver, resulting in ischemia of the supplied hepatic parenchyma [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/73\" class=\"abstract_t\">73</a>]. Ischemia leads to atrophy of the more vulnerable regions of the liver around the central vein and compensatory hypertrophy of the less vulnerable periportal areas [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/74\" class=\"abstract_t\">74</a>]. Studies of human livers from patients with acute or chronic portal vein thrombosis have demonstrated apoptosis, atrophy, and the development of nodules [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/73\" class=\"abstract_t\">73</a>]. In some cases, the primary insult to the liver was arterial rather than venous. The resulting periportal inflammation eventually leads to portal venopathy [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/68-70,73-76\" class=\"abstract_t\">68-70,73-76</a>].</p><p>T cell-induced autoimmune mechanisms have also been implicated in the development of the portal vein injury [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/77\" class=\"abstract_t\">77</a>]. In one report, sinusoidal infiltration with CD 8+ cytotoxic T cells was observed in 14 of 44 patients (32 percent) [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/71\" class=\"abstract_t\">71</a>]. The T cells were located mainly in the atrophic areas and were adjacent to endothelial cells exhibiting evidence of apoptosis. The authors speculated that transient T cell-induced endothelial injury may be the trigger for the development of idiopathic noncirrhotic portal hypertension. Another study found that 77 percent of patients with idiopathic noncirrhotic portal hypertension had antiphospholipid antibodies, possibly indicating an antibody-dependent autoimmune mechanism [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/78\" class=\"abstract_t\">78</a>].</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h2\">Clinical manifestations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>As the name implies, idiopathic noncirrhotic portal hypertension is characterized by portal hypertension. Typically, liver function is preserved, even when portal hypertension is clinically evident. Liver failure with ascites <span class=\"nowrap\">and/or</span> encephalopathy is rare [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/70,73,79\" class=\"abstract_t\">70,73,79</a>]. (See <a href=\"topic.htm?path=portal-hypertension-in-adults#H72827922\" class=\"medical medical_review\">&quot;Portal hypertension in adults&quot;, section on 'Clinical manifestations'</a>.)</p><p>The most common clinical presentation is variceal bleeding, which (in contrast to variceal bleeding in cirrhosis) is often relatively well tolerated due to the preserved liver function. In the late stages of the disease or following an episode of gastrointestinal bleeding, patients will occasionally develop jaundice, ascites, or hepatic encephalopathy. Hepatopulmonary syndrome has been described and reverses after liver transplantation [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/80-82\" class=\"abstract_t\">80-82</a>]. Development of portal vein thrombosis is a frequent event during the natural course of the disease, particularly in patients with associated HIV infection [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/83\" class=\"abstract_t\">83</a>]. </p><p>On clinical examination, massive splenomegaly (&gt;10 cm below the left subcostal margin) is present in more than 95 percent of patients. Dilated superficial abdominal veins can be seen in 15 percent of patients, and mild hepatomegaly (&lt;4 cm below the right subcostal margin) can be found in 50 percent of patients [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/33\" class=\"abstract_t\">33</a>]. Other stigmata of chronic liver disease are usually absent.</p><p>Liver biochemical tests are usually normal or nearly normal [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/38,70,73\" class=\"abstract_t\">38,70,73</a>]. Anemia, leukopenia, and thrombocytopenia are common because of hypersplenism. (See <a href=\"topic.htm?path=approach-to-the-adult-with-splenomegaly-and-other-splenic-disorders#H4\" class=\"medical medical_review\">&quot;Approach to the adult with splenomegaly and other splenic disorders&quot;, section on 'Hypersplenism'</a> and <a href=\"topic.htm?path=approach-to-the-adult-with-splenomegaly-and-other-splenic-disorders#H30\" class=\"medical medical_review\">&quot;Approach to the adult with splenomegaly and other splenic disorders&quot;, section on 'CBC and peripheral smear'</a>.)</p><p>Imaging findings that have been described in patients with idiopathic noncirrhotic portal hypertension include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Ultrasonography: Isoechoic nodules. The nodules can also be hypoechoic, often with a hypoechoic rim, features that can mistakenly suggest hepatic metastases [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/36,84\" class=\"abstract_t\">36,84</a>].<strong> </strong></p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Computed tomography (CT) scanning: Nonspecifically hypodense nodules on CT [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/36,84\" class=\"abstract_t\">36,84</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Magnetic resonance imaging (MRI): Isointense nodules on T2-weighted images that contain foci of high intensity on T1-weighted images [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/36,85-87\" class=\"abstract_t\">36,85-87</a>].</p><p/><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">Diagnosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of idiopathic noncirrhotic portal hypertension is based on the presence of unequivocal portal hypertension, histologic exclusion of cirrhosis, and exclusion of other disorders that may cause noncirrhotic portal hypertension [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/88\" class=\"abstract_t\">88</a>]. (See <a href=\"#H64319454\" class=\"local\">'Etiology'</a> above.)</p><p>Patients who have histologic findings consistent with idiopathic noncirrhotic portal hypertension, but who do not have evidence of portal hypertension, are not considered to have idiopathic noncirrhotic portal hypertension. In a series of 2500 autopsies, histologic findings consistent with idiopathic noncirrhotic portal hypertension were found in 3 percent. However, of that 3 percent, only 5 percent had evidence of portal hypertension.</p><p class=\"headingAnchor\" id=\"H64321128\"><span class=\"h3\">Diagnostic approach</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnostic approach in a patient suspected of having idiopathic noncirrhotic portal hypertension includes the following: laboratory tests to rule out other causes of liver <span class=\"nowrap\">disease/noncirrhotic</span> portal hypertension, history of drug or toxin exposure, hepatic imaging to rule out portal or hepatic vein occlusion, and liver biopsy to rule out cirrhosis.</p><p>To aid with the identification of patients with idiopathic noncirrhotic portal hypertension, diagnostic criteria have been proposed. A diagnosis of idiopathic noncirrhotic portal hypertension requires that all of the following criteria be met [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/1\" class=\"abstract_t\">1</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Clinical signs of portal hypertension (at least one of the following) must be present:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><span class=\"nowrap\">Splenomegaly/hypersplenism</span> in conjunction with another sign of portal hypertension</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Esophageal <span class=\"nowrap\">and/or</span> gastric varices</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Ascites (nonmalignant)</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Increased hepatic venous pressure gradient</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Portovenous collaterals</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Exclusion of cirrhosis on liver biopsy</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Exclusion of chronic liver disease that may cause either cirrhosis or noncirrhotic portal hypertension:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Chronic hepatitis B or C virus infection (see <a href=\"topic.htm?path=hepatitis-b-virus-screening-and-diagnosis\" class=\"medical medical_review\">&quot;Hepatitis B virus: Screening and diagnosis&quot;</a> and <a href=\"topic.htm?path=diagnosis-and-evaluation-of-chronic-hepatitis-c-virus-infection#H1128801959\" class=\"medical medical_review\">&quot;Diagnosis and evaluation of chronic hepatitis C virus infection&quot;, section on 'Diagnostic tests'</a>)</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Nonalcoholic steatohepatitis (see <a href=\"topic.htm?path=epidemiology-clinical-features-and-diagnosis-of-nonalcoholic-fatty-liver-disease-in-adults#H8\" class=\"medical medical_review\">&quot;Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults&quot;, section on 'Diagnosis'</a>)</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Alcoholic steatohepatitis (see <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-alcoholic-fatty-liver-disease-and-alcoholic-cirrhosis#H1680469\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of alcoholic fatty liver disease and alcoholic cirrhosis&quot;, section on 'Diagnosis'</a>)</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Autoimmune hepatitis (see <a href=\"topic.htm?path=autoimmune-hepatitis-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Autoimmune hepatitis: Clinical manifestations and diagnosis&quot;</a>)</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Hereditary hemochromatosis (see <a href=\"topic.htm?path=approach-to-the-patient-with-suspected-iron-overload#H746968\" class=\"medical medical_review\">&quot;Approach to the patient with suspected iron overload&quot;, section on 'Diagnosis'</a>)</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Wilson disease (see <a href=\"topic.htm?path=wilson-disease-clinical-manifestations-diagnosis-and-natural-history#H65234856\" class=\"medical medical_review\">&quot;Wilson disease: Clinical manifestations, diagnosis, and natural history&quot;, section on 'Diagnosis'</a>)</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Primary biliary cirrhosis (see <a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-prognosis-of-primary-biliary-cholangitis-primary-biliary-cirrhosis#H58140621\" class=\"medical medical_review\">&quot;Clinical manifestations, diagnosis, and prognosis of primary biliary cholangitis (primary biliary cirrhosis)&quot;, section on 'Diagnosis'</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Exclusion of other conditions that may cause noncirrhotic portal hypertension:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Congenital liver fibrosis</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Sarcoidosis (see <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of pulmonary sarcoidosis&quot;</a>)</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Schistosomiasis (see <a href=\"#H64323358\" class=\"local\">'Schistosomiasis'</a> above)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Imaging showing patent portal and hepatic veins</p><p/><p>Patients should be evaluated for the disorders associated with idiopathic noncirrhotic portal hypertension (<a href=\"image.htm?imageKey=GAST%2F50663\" class=\"graphic graphic_table graphicRef50663 \">table 2</a>) if they have signs or symptoms of any of the conditions, hematologic manifestations of a myeloproliferative disease on the complete blood count and differential, prior thrombotic events that might reflect an underlying hypercoagulable state, or manifestations suggestive of a systemic disease associated with vascular injury (eg, vasculitis, lupus). (See <a href=\"topic.htm?path=overview-of-the-myeloproliferative-neoplasms#H7\" class=\"medical medical_review\">&quot;Overview of the myeloproliferative neoplasms&quot;, section on 'Diagnosis'</a> and <a href=\"topic.htm?path=evaluating-adult-patients-with-established-venous-thromboembolism-for-acquired-and-inherited-risk-factors\" class=\"medical medical_review\">&quot;Evaluating adult patients with established venous thromboembolism for acquired and inherited risk factors&quot;</a> and <a href=\"#H64319454\" class=\"local\">'Etiology'</a> above.). </p><p class=\"headingAnchor\" id=\"H165946062\"><span class=\"h3\">Laboratory tests</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A report has suggested that serum vitamin B12 levels are significantly lower in patients with idiopathic noncirrhotic portal hypertension than in patients with cirrhosis and may be useful in distinguishing between the two entities [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/89\" class=\"abstract_t\">89</a>]. However, the potential diagnostic role of serum vitamin B12 levels has not been validated. Similarly, it has been suggested, but not yet validated, that a group of serum metabolites detected by metabolomics may aid with diagnosing idiopathic noncirrhotic portal hypertension [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/90\" class=\"abstract_t\">90</a>].</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h3\">Imaging</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>An imaging test is required to evaluate the liver parenchyma and circulation. The portal and hepatic veins in idiopathic noncirrhotic portal hypertension should be patent on imaging by Doppler ultrasound, CT angiography, or MRI angiography, though patients with advanced disease may have secondary portal vein thrombosis. Secondary portal vein thrombosis may then be misdiagnosed as primary extrahepatic portal vein thrombosis or thrombosis secondary to underlying cirrhosis. The clinical history, liver stiffness values, and liver biopsy findings may help to differentiate between these entities.</p><p class=\"headingAnchor\" id=\"H625703682\"><span class=\"h3\">Liver stiffness</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A patient with idiopathic noncirrhotic portal hypertension should have a liver stiffness value on transient elastography that is far below what would be expected in a patient with cirrhosis. This can be helpful in differentiating patients with portal vein thrombosis due to cirrhosis from those with portal vein thrombosis in the setting of idiopathic noncirrhotic portal hypertension [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/49\" class=\"abstract_t\">49</a>]. (See <a href=\"topic.htm?path=noninvasive-assessment-of-hepatic-fibrosis-ultrasound-based-elastography#H8550330\" class=\"medical medical_review\">&quot;Noninvasive assessment of hepatic fibrosis: Ultrasound-based elastography&quot;, section on 'Transient elastography'</a>.)</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h3\">Liver pathology</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>From a clinical perspective, the most important reason to obtain a liver biopsy in the evaluation of idiopathic noncirrhotic portal hypertension is to exclude the presence of cirrhosis and other specific disease entities that could account for the development of portal hypertension. Percutaneous or transjugular biopsy may not be sufficient because of the sampling variability, so patients suspected of having idiopathic noncirrhotic portal hypertension who have an unrevealing core needle biopsy may require an open or laparoscopic biopsy [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/73,74,77,91,92\" class=\"abstract_t\">73,74,77,91,92</a>]. (See <a href=\"topic.htm?path=approach-to-liver-biopsy\" class=\"medical medical_review\">&quot;Approach to liver biopsy&quot;</a>.)</p><p>Gross pathology of the liver surface in patients with idiopathic noncirrhotic portal hypertension is normal in most patients, but it is markedly nodular in 10 to 15 percent of patients, with nodularity confined to the liver's surface [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/40\" class=\"abstract_t\">40</a>]. The portal vein and its branches are prominent with sclerosed walls. Autopsy specimens often demonstrate the presence of thrombi in the small and medium portal vein branches [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/93\" class=\"abstract_t\">93</a>].</p><p>Historically, idiopathic noncirrhotic portal hypertension was classified into one of four histologic categories: idiopathic portal hypertension, nodular regenerative hyperplasia, partial nodular transformation, and incomplete septal cirrhosis:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Idiopathic portal hypertension was defined by the presence of fibrotic portal tracts and thin fibrous septa without evidence of cirrhosis.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Nodular regenerative hyperplasia was defined by micronodular transformation of the liver parenchyma, with central hyperplasia, an atrophic rim, and no fibrosis.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Partial nodular transformation was characterized by noncirrhotic, grossly visible parenchymal nodules that are located in the perihilar region of the liver around the large portal tracts.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Incomplete septal cirrhosis was defined by slender, incomplete septal fibrosis that demarcates the liver parenchyma into nodules. The portal tracts are hypoplastic and hepatocytes are hyperplastic.</p><p/><p>However, it is now appreciated that patients often have features of more than one classification. Some of the variability in histologic findings among patients may be the result of heterogeneity in the disease and its severity and because of sampling variability on liver biopsy specimens (<a href=\"image.htm?imageKey=GAST%2F80624\" class=\"graphic graphic_table graphicRef80624 \">table 3</a>) [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/37,40,61,94\" class=\"abstract_t\">37,40,61,94</a>].</p><p>A common finding associated with idiopathic noncirrhotic portal hypertension is obliteration of small portal venules (occlusive venopathy) that may lead to impairment in the intrahepatic portal perfusion and parenchymal atrophy. Other typical histological findings include an &quot;obliterative portal venopathy of liver&quot; (characterized by irregular sclerosis of the portal vein wall), fibrosis of the portal tract, dilatation of sinusoids due to increased portal pressure, and emergence of new aberrant portal channels (<a href=\"image.htm?imageKey=GAST%2F63404%7EGAST%2F51618\" class=\"graphic graphic_picture graphicRef63404 graphicRef51618 \">picture 3A-B</a>) [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/95\" class=\"abstract_t\">95</a>]. In advanced cases, parenchymal atrophy in the subcapsular regions may lead to collapse [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/37,94,96,97\" class=\"abstract_t\">37,94,96,97</a>]. Uncommon histologic features include pseudonodules, piecemeal necrosis, and regenerative activity [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/93\" class=\"abstract_t\">93</a>]. Regenerative nodules may develop near the hilum of atrophic livers in advanced cases. Electron microscopy has revealed widening of the space of Disse with fibrogenesis in the perisinusoidal space leading to capillarization of the sinusoids in some patients [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/43\" class=\"abstract_t\">43</a>].</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h3\">Hemodynamics</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Intrasplenic and portal vein pressures are markedly elevated in patients with idiopathic noncirrhotic portal hypertension [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/98,99\" class=\"abstract_t\">98,99</a>]. The wedged hepatic vein pressure (WHVP) is normal or slightly elevated in approximately half of patients. The WHVP, along with the free hepatic venous pressure (which reflects intraabdominal pressure), are used to determine the hepatic venous pressure gradient (HVPG), which estimates the severity of portal hypertension. Despite unequivocal signs of portal hypertension such as large esophageal varices and splenomegaly, HVPG values in patients with idiopathic noncirrhotic portal hypertension are much lower than the cutoff for clinically significant portal hypertension in cirrhosis [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/100\" class=\"abstract_t\">100</a>]. In addition, hepatic vein-to-vein communications are frequently seen during venography in idiopathic noncirrhotic portal hypertension. In the presence of these intrahepatic venous communications, the WHVP almost always underestimates the true portal pressure because communications between the hepatic veins often preclude correct positioning and occlusion of the balloon catheter [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/101,102\" class=\"abstract_t\">101,102</a>]. Demonstration of such communication during hepatic venography is supportive of the diagnosis. (See <a href=\"topic.htm?path=portal-hypertension-in-adults#H72827684\" class=\"medical medical_review\">&quot;Portal hypertension in adults&quot;, section on 'Hepatic venous pressure gradient'</a>.)</p><p class=\"headingAnchor\" id=\"H64320430\"><span class=\"h2\">Differential diagnosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The differential diagnosis includes portal hypertension due to cirrhosis of any etiology and a variety of pre-, intra-, or postsinusoidal disorders associated with portal hypertension (<a href=\"image.htm?imageKey=GAST%2F76516\" class=\"graphic graphic_table graphicRef76516 \">table 1</a>). The diagnosis of idiopathic noncirrhotic portal hypertension includes ruling out these other disorders. (See <a href=\"#H64319454\" class=\"local\">'Etiology'</a> above and <a href=\"#H64321128\" class=\"local\">'Diagnostic approach'</a> above.)</p><p class=\"headingAnchor\" id=\"H18\"><span class=\"h2\">Management</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The key issues in the management of patients with idiopathic noncirrhotic portal hypertension are related mainly to management and prevention of variceal hemorrhage. While data are limited in this population regarding the best approach [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/83,103-107\" class=\"abstract_t\">83,103-107</a>], patients are typically managed in the same manner as those with portal hypertension due to cirrhosis. A cohort study of patients with idiopathic noncirrhotic portal hypertension reported good long-term outcomes using a management strategy based on guidelines for varices in the setting of cirrhosis [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/83\" class=\"abstract_t\">83</a>]. Other elements of management include withdrawing drugs associated with idiopathic noncirrhotic portal hypertension and treating associated medical conditions (<a href=\"image.htm?imageKey=GAST%2F50663\" class=\"graphic graphic_table graphicRef50663 \">table 2</a>). As an example, biochemical and histologic improvement or reversibility has been reported after stopping <a href=\"topic.htm?path=azathioprine-drug-information\" class=\"drug drug_general\">azathioprine</a> in organ transplantation recipients [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/85,108\" class=\"abstract_t\">85,108</a>]. In addition, patients with idiopathic portal hypertension should be screened for portal vein thrombosis (eg, with Doppler ultrasonography every six months [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/109\" class=\"abstract_t\">109</a>]). (See <a href=\"#H64319454\" class=\"local\">'Etiology'</a> above.)</p><p>Treatment for acute variceal bleeding includes early pharmacologic treatment with vasoactive drugs, early endoscopic control of bleeding, careful blood product replacement, and prophylactic antibiotics. (See <a href=\"topic.htm?path=general-principles-of-the-management-of-variceal-hemorrhage\" class=\"medical medical_review\">&quot;General principles of the management of variceal hemorrhage&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1543171122\"><span class=\"h3\">Non-selective beta blockers and endoscopic variceal ligation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Primary and secondary prevention of variceal bleeding includes the use of nonselective beta blockers and endoscopic variceal ligation. Data from cohort studies suggest that strategies based on the recommendations for management of cirrhotic portal hypertension can be applied to patients with noncirrhotic portal hypertension, and that this approach results in similar outcomes [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/83,110\" class=\"abstract_t\">83,110</a>].</p><p class=\"headingAnchor\" id=\"H4061179689\"><span class=\"h3\">Portosystemic shunt surgery</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Portosystemic shunt surgery is an effective alternative for patients who fail endoscopic therapy [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/111-113\" class=\"abstract_t\">111-113</a>]. However, shunt surgery has largely been replaced by transjugular intrahepatic portosystemic shunting. </p><p class=\"headingAnchor\" id=\"H1854138629\"><span class=\"h3\">Transjugular intrahepatic portosystemic shunt (TIPS)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>TIPS is an option for treatment of complications of idiopathic noncirrhotic portal hypertension, but should be avoided in patients with poor renal function, ascites, and significant extrahepatic comorbidities (eg, prothrombotic condition, hematologic malignancy, solid organ transplantation) [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/114\" class=\"abstract_t\">114</a>]. In a study of 41 patients with idiopathic noncirrhotic portal hypertension who underwent TIPS with a mean follow-up of 27 months, seven of 25 patients with a history of variceal bleeding had recurrent bleeding (28 percent). The risk of mortality was higher in patients with extrahepatic comorbidities and elevated creatinine.</p><p class=\"headingAnchor\" id=\"H568848246\"><span class=\"h3\">Other interventions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Several other interventions for idiopathic noncirrhotic portal hypertension have been reported [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/40,107,115\" class=\"abstract_t\">40,107,115</a>]. Splenectomy has been described in patients with symptomatic hypersplenism (spontaneous bleeding episodes, severe transfusion-dependent anemia, or repeated splenic infarcts) [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/40\" class=\"abstract_t\">40</a>]. Case reports of patients with idiopathic noncirrhotic portal hypertension have also described splenic embolization and percutaneous transhepatic obliteration [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/107,115\" class=\"abstract_t\">107,115</a>]. (See <a href=\"topic.htm?path=primary-and-pre-primary-prophylaxis-against-variceal-hemorrhage-in-patients-with-cirrhosis\" class=\"medical medical_review\">&quot;Primary and pre-primary prophylaxis against variceal hemorrhage in patients with cirrhosis&quot;</a> and <a href=\"topic.htm?path=prevention-of-recurrent-variceal-hemorrhage-in-patients-with-cirrhosis\" class=\"medical medical_review\">&quot;Prevention of recurrent variceal hemorrhage in patients with cirrhosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H21\"><span class=\"h2\">Prognosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Because of preserved liver function, the prognosis of patients with idiopathic noncirrhotic portal hypertension is better than that of patients with cirrhosis who have a similar degree of portal hypertension. However, a subgroup of patients progresses to develop advanced hepatic insufficiency, eventually requiring liver transplantation [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/116,117\" class=\"abstract_t\">116,117</a>]. These patients generally have nodular transformation of the liver with extensive hepatic and portal fibrosis. A few case reports have suggested an association between idiopathic noncirrhotic portal hypertension and hepatocellular carcinoma, but whether other risk factors may have accounted for the observation is unclear [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/118,119\" class=\"abstract_t\">118,119</a>]. Currently, screening for hepatocellular carcinoma is not recommended for these patients.</p><p>There are very few studies evaluating the long-term prognosis of patients with idiopathic noncirrhotic portal hypertension:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>One cohort study of Western patients suggested that overall survival was poorer compared with that of the general population, with a transplant-free survival of only 40 percent at 10 years [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/120\" class=\"abstract_t\">120</a>]. However, the increased mortality in this study was related to non-liver related conditions and not to complications of portal hypertension or liver failure. Only 4 of 62 patients (6.5 percent) died from liver-related conditions.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>By contrast, another study reported good long-term outcomes in patients with biopsy-proven idiopathic noncirrhotic portal hypertension, with a 10-year transplant-free survival rate of 82 percent [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/83\" class=\"abstract_t\">83</a>].</p><p/><p>In both studies, the development of ascites was identified as a poor prognostic factor in patients with idiopathic noncirrhotic portal hypertension. In the latter study, the presence of a severe associated disorder (immunological disease or malignancy) was also identified as a poor prognostic factor [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/83\" class=\"abstract_t\">83</a>].</p><p class=\"headingAnchor\" id=\"H2251068476\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-portal-hypertension-and-ascites\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Portal hypertension and ascites&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H27\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cirrhosis is the most common cause of portal hypertension, but portal hypertension can also occur in the absence of cirrhosis, a condition referred to as &quot;noncirrhotic portal hypertension.&quot; The causes of noncirrhotic portal hypertension can be divided into prehepatic, intrahepatic (presinusoidal, sinusoidal, and postsinusoidal), and posthepatic causes (<a href=\"image.htm?imageKey=GAST%2F76516\" class=\"graphic graphic_table graphicRef76516 \">table 1</a>). (See <a href=\"#H64319454\" class=\"local\">'Etiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Schistosomiasis is one of the most common causes of noncirrhotic portal hypertension worldwide [<a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/6\" class=\"abstract_t\">6</a>].</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Chronic hepatic schistosomiasis is characterized by features of portal hypertension: esophageal varices, hepatomegaly, and splenomegaly with hypersplenism. (See <a href=\"#H64323370\" class=\"local\">'Clinical features'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>The diagnosis of schistosomiasis can be made by the detection of schistosomal eggs in the stool. (See <a href=\"#H64323394\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>In addition to treating the underlying parasitic infection, management is aimed at preventing or treating the consequences of portal hypertension (predominantly variceal bleeding). (See <a href=\"#H64323400\" class=\"local\">'Management'</a> above and <a href=\"topic.htm?path=treatment-and-prevention-of-schistosomiasis#H13464830\" class=\"medical medical_review\">&quot;Treatment and prevention of schistosomiasis&quot;, section on 'Treatment'</a> and <a href=\"topic.htm?path=general-principles-of-the-management-of-variceal-hemorrhage\" class=\"medical medical_review\">&quot;General principles of the management of variceal hemorrhage&quot;</a> and <a href=\"topic.htm?path=methods-to-achieve-hemostasis-in-patients-with-acute-variceal-hemorrhage\" class=\"medical medical_review\">&quot;Methods to achieve hemostasis in patients with acute variceal hemorrhage&quot;</a> and <a href=\"topic.htm?path=primary-and-pre-primary-prophylaxis-against-variceal-hemorrhage-in-patients-with-cirrhosis\" class=\"medical medical_review\">&quot;Primary and pre-primary prophylaxis against variceal hemorrhage in patients with cirrhosis&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Idiopathic noncirrhotic portal hypertension has been referred to by several different names, including nodular regenerative hyperplasia. It is characterized by portal hypertension in the absence of liver cirrhosis, with histologic features of dense portal fibrosis, marked phlebosclerosis, and dilated sinusoids.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>The most common clinical presentation is variceal bleeding, which is often relatively well tolerated due to the preserved liver function. Development of portal vein thrombosis is a frequent event during the natural course of the disease, mainly in those with associated human immunodeficiency virus infection. (See <a href=\"#H11\" class=\"local\">'Clinical manifestations'</a> above.) </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>The diagnostic approach in a patient suspected of having idiopathic noncirrhotic portal hypertension includes the following: laboratory tests to rule out other causes of liver <span class=\"nowrap\">disease/noncirrhotic</span> portal hypertension, hepatic imaging to rule out portal or hepatic vein occlusion, and liver biopsy to rule out cirrhosis. The differential diagnosis includes portal hypertension due to cirrhosis of any etiology and a variety of pre-, intra-, or postsinusoidal disorders associated with portal hypertension (<a href=\"image.htm?imageKey=GAST%2F76516\" class=\"graphic graphic_table graphicRef76516 \">table 1</a>). (See <a href=\"#H64319454\" class=\"local\">'Etiology'</a> above and <a href=\"#H12\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>As with noncirrhotic portal hypertension due to schistosomiasis, management is aimed at preventing or treating the consequences of portal hypertension (predominantly variceal bleeding). While data are limited in this population regarding the best approach to management, patients are typically managed in the same manner as those with portal hypertension due to cirrhosis. Patients should also undergo screening for portal vein thrombosis (eg, with Doppler ultrasonography every six months). (See <a href=\"#H18\" class=\"local\">'Management'</a> above and <a href=\"topic.htm?path=treatment-and-prevention-of-schistosomiasis#H13464830\" class=\"medical medical_review\">&quot;Treatment and prevention of schistosomiasis&quot;, section on 'Treatment'</a> and <a href=\"topic.htm?path=general-principles-of-the-management-of-variceal-hemorrhage\" class=\"medical medical_review\">&quot;General principles of the management of variceal hemorrhage&quot;</a> and <a href=\"topic.htm?path=methods-to-achieve-hemostasis-in-patients-with-acute-variceal-hemorrhage\" class=\"medical medical_review\">&quot;Methods to achieve hemostasis in patients with acute variceal hemorrhage&quot;</a> and <a href=\"topic.htm?path=primary-and-pre-primary-prophylaxis-against-variceal-hemorrhage-in-patients-with-cirrhosis\" class=\"medical medical_review\">&quot;Primary and pre-primary prophylaxis against variceal hemorrhage in patients with cirrhosis&quot;</a>.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/1\" class=\"nounderline abstract_t\">Schouten JN, Garcia-Pagan JC, Valla DC, Janssen HL. Idiopathic noncirrhotic portal hypertension. Hepatology 2011; 54:1071.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/2\" class=\"nounderline abstract_t\">Morris JS, Schmid M, Newman S, et al. Arsenic and noncirrhotic portal hypertension. Gastroenterology 1974; 66:86.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/3\" class=\"nounderline abstract_t\">Datta DV, Mitra SK, Chhuttani PN, Chakravarti RN. Chronic oral arsenic intoxication as a possible aetiological factor in idiopathic portal hypertension (non-cirrhotic portal fibrosis) in India. Gut 1979; 20:378.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/4\" class=\"nounderline abstract_t\">Sarin SK, Sharma G, Banerjee S, et al. Hepatic fibrogenesis using chronic arsenic ingestion: studies in a murine model. Indian J Exp Biol 1999; 37:147.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/5\" class=\"nounderline abstract_t\">Smith PM, Crossley IR, Williams DM. Portal hypertension in vinyl-chloride production workers. Lancet 1976; 2:602.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/6\" class=\"nounderline abstract_t\">Dunn MA, Kamel R. Hepatic schistosomiasis. Hepatology 1981; 1:653.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/7\" class=\"nounderline abstract_t\">El-Garem AA. Schistosomiasis. Digestion 1998; 59:589.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/8\" class=\"nounderline abstract_t\">Nakashima, T. Liver cirrhosis. Human cases. Acta Hepatol Jpn 1969; 10:485.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/9\" class=\"nounderline abstract_t\">Da Silva LC, Carrilho FJ. Hepatosplenic schistosomiasis. Pathophysiology and treatment. Gastroenterol Clin North Am 1992; 21:163.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/10\" class=\"nounderline abstract_t\">Deni&eacute; C, Vachiery F, Elman A, et al. Systemic and splanchnic hemodynamic changes in patients with hepatic schistosomiasis. Liver 1996; 16:309.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/11\" class=\"nounderline abstract_t\">Mies S, Neto OB, Beer A Jr, et al. Systemic and hepatic hemodynamics in hepatosplenic Manson's schistosomiasis with and without propranolol. Dig Dis Sci 1997; 42:751.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/12\" class=\"nounderline abstract_t\">Pereira LM, Melo MC, Saleh MG, et al. Hepatitis C virus infection in Schistosomiasis mansoni in Brazil. J Med Virol 1995; 45:423.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/13\" class=\"nounderline abstract_t\">Pereira LM, Melo MC, Lacerda C, et al. Hepatitis B virus infection in schistosomiasis mansoni. J Med Virol 1994; 42:203.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/14\" class=\"nounderline abstract_t\">Strickland GT, Elhefni H, Salman T, et al. Role of hepatitis C infection in chronic liver disease in Egypt. Am J Trop Med Hyg 2002; 67:436.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/15\" class=\"nounderline abstract_t\">de Cleva R, Herman P, Pugliese V, et al. Prevalence of pulmonary hypertension in patients with hepatosplenic Mansonic schistosomiasis--prospective study. Hepatogastroenterology 2003; 50:2028.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/16\" class=\"nounderline abstract_t\">Wynn TA, Thompson RW, Cheever AW, Mentink-Kane MM. Immunopathogenesis of schistosomiasis. Immunol Rev 2004; 201:156.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/17\" class=\"nounderline abstract_t\">Berhe N, Gundersen SG, Abebe F, et al. Praziquantel side effects and efficacy related to Schistosoma mansoni egg loads and morbidity in primary school children in north-east Ethiopia. Acta Trop 1999; 72:53.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/18\" class=\"nounderline abstract_t\">Davis A, Wegner DH. Multicentre trials of praziquantel in human schistosomiasis: design and techniques. Bull World Health Organ 1979; 57:767.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/19\" class=\"nounderline abstract_t\">de Franchis R, Baveno V Faculty. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2010; 53:762.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/20\" class=\"nounderline abstract_t\">da Silva LC, Strauss E, Gayotto LC, et al. A randomized trial for the study of the elective surgical treatment of portal hypertension in mansonic schistosomiasis. Ann Surg 1986; 204:148.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/21\" class=\"nounderline abstract_t\">Andersson KL, Chung RT. Hepatic schistosomiasis. Curr Treat Options Gastroenterol 2007; 10:504.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/22\" class=\"nounderline abstract_t\">Costa Lacet CM, Neto JB, Ribeiro LT, et al. Schistosomal portal hypertension: Randomized trial comparing endoscopic therapy alone or preceded by esophagogastric devascularization and splenectomy. Ann Hepatol 2016; 15:738.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/23\" class=\"nounderline abstract_t\">Raia S, da Silva LC, Gayotto LC, et al. Portal hypertension in schistosomiasis: a long-term follow-up of a randomized trial comparing three types of surgery. Hepatology 1994; 20:398.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/24\" class=\"nounderline abstract_t\">Okuda K, Nakashima T, Okudaira M, et al. Liver pathology of idiopathic portal hypertension. Comparison with non-cirrhotic portal fibrosis of India. The Japan idiopathic portal hypertension study. Liver 1982; 2:176.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/25\" class=\"nounderline abstract_t\">Boyer JL, Sen Gupta KP, Biswas SK, et al. Idiopathic portal hypertension. Comparison with the portal hypertension of cirrhosis and extrahepatic portal vein obstruction. Ann Intern Med 1967; 66:41.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/26\" class=\"nounderline abstract_t\">HALLENBECK GA, ADSON MA. Esophagogastric varices without hepatic cirrhosis. A clinical study of treatment for their bleeding in 72 cases. Arch Surg 1961; 83:370.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/27\" class=\"nounderline abstract_t\">LEATHER HM. Portal hypertension and gross splenomegaly in Uganda. Br Med J 1961; 1:15.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/28\" class=\"nounderline abstract_t\">POLISH E, CHRISTIE J, COHEN A, SULLIVAN B Jr. Idiopathic presinusoidal portal hypertension (Banti's syndrome). Ann Intern Med 1962; 56:624.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/29\" class=\"nounderline abstract_t\">MILLER MC, BRANDT JL. Portal hypertension in the absence of both liver disease and vascular obstruction. Am J Dig Dis 1962; 7:442.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/30\" class=\"nounderline abstract_t\">COOK J, McFADZEAN AJ, TODD D. Splenectomy in cryptogenetic splenomegaly. Br Med J 1963; 2:337.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/31\" class=\"nounderline abstract_t\">SIDERYS H, VELLIOS F. PORTAL HYPERTENSION WITHOUT CIRRHOSIS OR EXTRAHEPATIC OBSTRUCTION. REPORT OF A CASE. Am J Surg 1964; 108:785.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/32\" class=\"nounderline abstract_t\">Sama SK, Bhargava S, Nath NG, et al. Noncirrhotic portal fibrosis. Am J Med 1971; 51:160.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/33\" class=\"nounderline abstract_t\">Dhiman RK, Chawla Y, Vasishta RK, et al. Non-cirrhotic portal fibrosis (idiopathic portal hypertension): experience with 151 patients and a review of the literature. J Gastroenterol Hepatol 2002; 17:6.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/34\" class=\"nounderline abstract_t\">Sarin SK, Kumar A, Chawla YK, et al. Noncirrhotic portal fibrosis/idiopathic portal hypertension: APASL recommendations for diagnosis and treatment. Hepatol Int 2007; 1:398.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/35\" class=\"nounderline abstract_t\">Iber FL. Obliterative portal venopathy of the liver and &quot;idiopathic portal hypertension&quot;. Ann Intern Med 1969; 71:660.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/36\" class=\"nounderline abstract_t\">Mahamid J, Miselevich I, Attias D, et al. Nodular regenerative hyperplasia associated with idiopathic thrombocytopenic purpura in a young girl: a case report and review of the literature. J Pediatr Gastroenterol Nutr 2005; 41:251.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/37\" class=\"nounderline abstract_t\">Nakanuma Y, Hoso M, Sasaki M, et al. Histopathology of the liver in non-cirrhotic portal hypertension of unknown aetiology. Histopathology 1996; 28:195.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/38\" class=\"nounderline abstract_t\">Naber AH, Van Haelst U, Yap SH. Nodular regenerative hyperplasia of the liver: an important cause of portal hypertension in non-cirrhotic patients. J Hepatol 1991; 12:94.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/39\" class=\"nounderline abstract_t\">Vakili C, Farahvash MJ, Bynum TE. &quot;Endemic&quot; idiopathic portal hypertension: report on 32 patients with non-cirrhotic portal fibrosis. World J Surg 1992; 16:118.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/40\" class=\"nounderline abstract_t\">Sarin SK, Kapoor D. Non-cirrhotic portal fibrosis: current concepts and management. J Gastroenterol Hepatol 2002; 17:526.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/41\" class=\"nounderline abstract_t\">Okuda K. Non-cirrhotic portal hypertension versus idiopathic portal hypertension. J Gastroenterol Hepatol 2002; 17 Suppl 3:S204.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/42\" class=\"nounderline abstract_t\">Sarin SK, Aggarwal SR. Idiopathic portal hypertension. Digestion 1998; 59:420.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/43\" class=\"nounderline abstract_t\">Kono K, Ohnishi K, Omata M, et al. Experimental portal fibrosis produced by intraportal injection of killed nonpathogenic Escherichia coli in rabbits. Gastroenterology 1988; 94:787.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/44\" class=\"nounderline abstract_t\">Schiano TD, Kotler DP, Ferran E, Fiel MI. Hepatoportal sclerosis as a cause of noncirrhotic portal hypertension in patients with HIV. Am J Gastroenterol 2007; 102:2536.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/45\" class=\"nounderline abstract_t\">Mallet VO, Varthaman A, Lasne D, et al. Acquired protein S deficiency leads to obliterative portal venopathy and to compensatory nodular regenerative hyperplasia in HIV-infected patients. AIDS 2009; 23:1511.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/46\" class=\"nounderline abstract_t\">Kovari H, Ledergerber B, Peter U, et al. Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study. Clin Infect Dis 2009; 49:626.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/47\" class=\"nounderline abstract_t\">Maida I, Garcia-Gasco P, Sotgiu G, et al. Antiretroviral-associated portal hypertension: a new clinical condition? Prevalence, predictors and outcome. Antivir Ther 2008; 13:103.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/48\" class=\"nounderline abstract_t\">Saifee S, Joelson D, Braude J, et al. Noncirrhotic portal hypertension in patients with human immunodeficiency virus-1 infection. Clin Gastroenterol Hepatol 2008; 6:1167.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/49\" class=\"nounderline abstract_t\">Chang PE, Miquel R, Blanco JL, et al. Idiopathic portal hypertension in patients with HIV infection treated with highly active antiretroviral therapy. Am J Gastroenterol 2009; 104:1707.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/50\" class=\"nounderline abstract_t\">Schouten JN, Van der Ende ME, Ko&euml;ter T, et al. Risk factors and outcome of HIV-associated idiopathic noncirrhotic portal hypertension. Aliment Pharmacol Ther 2012; 36:875.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/51\" class=\"nounderline abstract_t\">Cachay ER, Peterson MR, Goicoechea M, Mathews WC. Didanosine Exposure and Noncirrhotic Portal Hypertension in a HIV Clinic in North America: a Follow-up Study. Br J Med Med Res 2011; 1:346.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/52\" class=\"nounderline abstract_t\">Vispo E, Morello J, Rodriguez-Novoa S, Soriano V. Noncirrhotic portal hypertension in HIV infection. Curr Opin Infect Dis 2011; 24:12.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/53\" class=\"nounderline abstract_t\">Nayyar AK, Sharma BK, Sarin SK, et al. Characterization of peripheral blood lymphocytes in patients with non-cirrhotic portal fibrosis: a comparison with cirrhotics and healthy controls. J Gastroenterol Hepatol 1990; 5:554.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/54\" class=\"nounderline abstract_t\">Tokushige K, Komatsu T, Ohzu K, et al. A defective autologous mixed lymphocyte reaction in patients with idiopathic portal hypertension. J Gastroenterol Hepatol 1992; 7:270.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/55\" class=\"nounderline abstract_t\">Saito K, Nakanuma Y, Takegoshi K, et al. Non-specific immunological abnormalities and association of autoimmune diseases in idiopathic portal hypertension. A study by questionnaire. Hepatogastroenterology 1993; 40:163.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/56\" class=\"nounderline abstract_t\">Inagaki H, Nonami T, Kawagoe T, et al. Idiopathic portal hypertension associated with systemic lupus erythematosus. J Gastroenterol 2000; 35:235.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/57\" class=\"nounderline abstract_t\">Tsuneyama K, Harada K, Katayanagi K, et al. Overlap of idiopathic portal hypertension and scleroderma: report of two autopsy cases and a review of literature. J Gastroenterol Hepatol 2002; 17:217.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/58\" class=\"nounderline abstract_t\">Pulvirenti F, Pentassuglio I, Milito C, et al. Idiopathic non cirrhotic portal hypertension and spleno-portal axis abnormalities in patients with severe primary antibody deficiencies. J Immunol Res 2014; 2014:672458.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/59\" class=\"nounderline abstract_t\">Vilarinho S, Sari S, Yilmaz G, et al. Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension. Hepatology 2016; 63:1977.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/60\" class=\"nounderline abstract_t\">Sarin SK, Mehra NK, Agarwal A, et al. Familial aggregation in noncirrhotic portal fibrosis: a report of four families. Am J Gastroenterol 1987; 82:1130.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/61\" class=\"nounderline abstract_t\">Hillaire S, Bonte E, Denninger MH, et al. Idiopathic non-cirrhotic intrahepatic portal hypertension in the West: a re-evaluation in 28 patients. Gut 2002; 51:275.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/62\" class=\"nounderline abstract_t\">K&ouml;ksal AS, K&ouml;kl&uuml; S, Ibi&#351; M, et al. Clinical features, serum interleukin-6, and interferon-gamma levels of 34 turkish patients with hepatoportal sclerosis. Dig Dis Sci 2007; 52:3493.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/63\" class=\"nounderline abstract_t\">Yamaguchi E, Yamanoi A, Ono T, Nagasue N. Experimental investigation of the role of endothelin-1 in idiopathic portal hypertension. J Gastroenterol Hepatol 2007; 22:1134.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/64\" class=\"nounderline abstract_t\">Kamath PS, Tyce GM, Miller VM, et al. Endothelin-1 modulates intrahepatic resistance in a rat model of noncirrhotic portal hypertension. Hepatology 1999; 30:401.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/65\" class=\"nounderline abstract_t\">Kamath PS, Carpenter HA, Lloyd RV, et al. Hepatic localization of endothelin-1 in patients with idiopathic portal hypertension and cirrhosis of the liver. Liver Transpl 2000; 6:596.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/66\" class=\"nounderline abstract_t\">Sato Y, Sawada S, Kozaka K, et al. Significance of enhanced expression of nitric oxide syntheses in splenic sinus lining cells in altered portal hemodynamics of idiopathic portal hypertension. Dig Dis Sci 2007; 52:1987.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/67\" class=\"nounderline abstract_t\">Morikawa H, Tamori A, Nishiguchi S, et al. Expression of connective tissue growth factor in the human liver with idiopathic portal hypertension. Mol Med 2007; 13:240.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/68\" class=\"nounderline abstract_t\">Krasinskas AM, Eghtesad B, Kamath PS, et al. Liver transplantation for severe intrahepatic noncirrhotic portal hypertension. Liver Transpl 2005; 11:627.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/69\" class=\"nounderline abstract_t\">Ibarrola C, Colina F. Clinicopathological features of nine cases of non-cirrhotic portal hypertension: current definitions and criteria are inadequate. Histopathology 2003; 42:251.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/70\" class=\"nounderline abstract_t\">Buchel O, Roskams T, Van Damme B, et al. Nodular regenerative hyperplasia, portal vein thrombosis, and avascular hip necrosis due to hyperhomocysteinaemia. Gut 2005; 54:1021.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/71\" class=\"nounderline abstract_t\">Ziol M, Poirel H, Kountchou GN, et al. Intrasinusoidal cytotoxic CD8+ T cells in nodular regenerative hyperplasia of the liver. Hum Pathol 2004; 35:1241.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/72\" class=\"nounderline abstract_t\">Youssef WI, Tavill AS. Connective tissue diseases and the liver. J Clin Gastroenterol 2002; 35:345.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/73\" class=\"nounderline abstract_t\">Al-Mukhaizeem KA, Rosenberg A, Sherker AH. Nodular regenerative hyperplasia of the liver: an under-recognized cause of portal hypertension in hematological disorders. Am J Hematol 2004; 75:225.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/74\" class=\"nounderline abstract_t\">Reshamwala PA, Kleiner DE, Heller T. Nodular regenerative hyperplasia: not all nodules are created equal. Hepatology 2006; 44:7.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/75\" class=\"nounderline abstract_t\">Podevin P, Spiridon G, Terris B, et al. Nodular regenerative hyperplasia of the liver after IL-2 therapy in an HIV-infected patient. AIDS 2006; 20:313.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/76\" class=\"nounderline abstract_t\">Reynolds WJ, Wanless IR. Nodular regenerative hyperplasia of the liver in a patient with rheumatoid vasculitis: a morphometric study suggesting a role for hepatic arteritis in the pathogenesis. J Rheumatol 1984; 11:838.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/77\" class=\"nounderline abstract_t\">Biecker E, Trebicka J, Fischer HP, et al. Portal hypertension and nodular regenerative hyperplasia in a patient with celiac disease. Z Gastroenterol 2006; 44:395.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/78\" class=\"nounderline abstract_t\">Klein R, Goller S, Bianchi L. Nodular regenerative hyperplasia (NRH) of the liver--a manifestation of 'organ-specific antiphospholipid syndrome'? Immunobiology 2003; 207:51.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/79\" class=\"nounderline abstract_t\">Seoane Urgorri A, Galeras Sadurni JA, Coll Estrada S, et al. [Ascites as the sole clinical manifestation in a patient with nodular regenerative hyperplasia]. Gastroenterol Hepatol 2003; 26:297.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/80\" class=\"nounderline abstract_t\">Babbs C, Warnes TW, Haboubi NY. Non-cirrhotic portal hypertension with hypoxaemia. Gut 1988; 29:129.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/81\" class=\"nounderline abstract_t\">Anand AC, Mukherjee D, Rao KS, Seth AK. Hepatopulmonary syndrome: prevalence and clinical profile. Indian J Gastroenterol 2001; 20:24.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/82\" class=\"nounderline abstract_t\">Martinez-Palli G, Drake BB, Garcia-Pagan JC, et al. Effect of transjugular intrahepatic portosystemic shunt on pulmonary gas exchange in patients with portal hypertension and hepatopulmonary syndrome. World J Gastroenterol 2005; 11:6858.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/83\" class=\"nounderline abstract_t\">Siramolpiwat S, Seijo S, Miquel R, et al. Idiopathic portal hypertension: natural history and long-term outcome. Hepatology 2014; 59:2276.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/84\" class=\"nounderline abstract_t\">Grattagliano A, Rapaccini GL, Caturelli E, et al. Nodular regenerative hyperplasia of the liver: ultrasonographic appearance and echo-guided bioptic diagnosis. Ital J Gastroenterol 1994; 26:349.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/85\" class=\"nounderline abstract_t\">Seiderer J, Zech CJ, Diebold J, et al. Nodular regenerative hyperplasia: a reversible entity associated with azathioprine therapy. Eur J Gastroenterol Hepatol 2006; 18:553.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/86\" class=\"nounderline abstract_t\">Horita T, Tsutsumi A, Takeda T, et al. Significance of magnetic resonance imaging in the diagnosis of nodular regenerative hyperplasia of the liver complicated with systemic lupus erythematosus: a case report and review of the literature. Lupus 2002; 11:193.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/87\" class=\"nounderline abstract_t\">Rha SE, Lee MG, Lee YS, et al. Nodular regenerative hyperplasia of the liver in Budd-Chiari syndrome: CT and MR features. Abdom Imaging 2000; 25:255.</a></li><li class=\"breakAll\">Okuda K, Nakashima T, Kameda H, et al. Idiopathic portal hypertension: a national study. In: Hepatology: a Festschrift for Hans Popper, Brunner H, Thaler H (Eds), Raven Press, New York 1985. p.95.</li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/89\" class=\"nounderline abstract_t\">Goel A, Ramakrishna B, Muliyil J, et al. Use of serum vitamin B12 level as a marker to differentiate idiopathic noncirrhotic intrahepatic portal hypertension from cryptogenic cirrhosis. Dig Dis Sci 2013; 58:179.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/90\" class=\"nounderline abstract_t\">Seijo S, Lozano JJ, Alonso C, et al. Metabolomics discloses potential biomarkers for the noninvasive diagnosis of idiopathic portal hypertension. Am J Gastroenterol 2013; 108:926.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/91\" class=\"nounderline abstract_t\">Krastev N, Grigorov N, Dinkov L, et al. [The role of laparoscopy and laparoscopic ultrasonography in the diagnosis and differential diagnosis of nodular hepatocellular lesions]. Khirurgiia (Sofiia) 1998; 53:14.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/92\" class=\"nounderline abstract_t\">Trauner M, Stepan KM, Resch M, et al. Diagnostic problems in nodular regenerative hyperplasia (nodular transformation) of the liver. Review of the literature and report of two cases. Z Gastroenterol 1992; 30:187.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/93\" class=\"nounderline abstract_t\">Okudaira M, Ohbu M, Okuda K. Idiopathic portal hypertension and its pathology. Semin Liver Dis 2002; 22:59.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/94\" class=\"nounderline abstract_t\">Ludwig J, Hashimoto E, Obata H, Baldus WP. Idiopathic portal hypertension; a histopathological study of 26 Japanese cases. Histopathology 1993; 22:227.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/95\" class=\"nounderline abstract_t\">Nayak NC, Ramalingaswami V. Obliterative portal venopathy of the liver. Associated with so-called idiopathic portal hypertension or tropical splenomegaly. Arch Pathol 1969; 87:359.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/96\" class=\"nounderline abstract_t\">Nakanuma Y, Tsuneyama K, Ohbu M, Katayanagi K. Pathology and pathogenesis of idiopathic portal hypertension with an emphasis on the liver. Pathol Res Pract 2001; 197:65.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/97\" class=\"nounderline abstract_t\">Aikat BK, Bhusnurmath SR, Chhuttani PN, et al. The pathology of noncirrhotic portal fibrosis: a review of 32 autopsy cases. Hum Pathol 1979; 10:405.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/98\" class=\"nounderline abstract_t\">Sarin SK, Sethi KK, Nanda R. Measurement and correlation of wedged hepatic, intrahepatic, intrasplenic and intravariceal pressures in patients with cirrhosis of liver and non-cirrhotic portal fibrosis. Gut 1987; 28:260.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/99\" class=\"nounderline abstract_t\">Ohnishi K, Sato S, Nomura F, Iida S. Splanchnic hemodynamics in idiopathic portal hypertension: comparison with chronic persistent hepatitis. Am J Gastroenterol 1989; 84:403.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/100\" class=\"nounderline abstract_t\">Seijo S, Reverter E, Miquel R, et al. Role of hepatic vein catheterisation and transient elastography in the diagnosis of idiopathic portal hypertension. Dig Liver Dis 2012; 44:855.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/101\" class=\"nounderline abstract_t\">Okuda K, Kono K, Ohnishi K, et al. Clinical study of eighty-six cases of idiopathic portal hypertension and comparison with cirrhosis with splenomegaly. Gastroenterology 1984; 86:600.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/102\" class=\"nounderline abstract_t\">Futagawa S, Fukazawa M, Musha H, et al. Hepatic venography in noncirrhotic idiopathic portal hypertension. Comparison with cirrhosis of the liver. Radiology 1981; 141:303.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/103\" class=\"nounderline abstract_t\">Sarin SK, Govil A, Jain AK, et al. Prospective randomized trial of endoscopic sclerotherapy versus variceal band ligation for esophageal varices: influence on gastropathy, gastric varices and variceal recurrence. J Hepatol 1997; 26:826.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/104\" class=\"nounderline abstract_t\">Kochhar R, Goenka MK, Mehta SK. Outcome of injection sclerotherapy using absolute alcohol in patients with cirrhosis, non-cirrhotic portal fibrosis, and extrahepatic portal venous obstruction. Gastrointest Endosc 1991; 37:460.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/105\" class=\"nounderline abstract_t\">Kiire CF. Controlled trial of propranolol to prevent recurrent variceal bleeding in patients with non-cirrhotic portal fibrosis. BMJ 1989; 298:1363.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/106\" class=\"nounderline abstract_t\">Sarin SK, Gupta N, Jha SK, et al. Equal efficacy of endoscopic variceal ligation and propranolol in preventing variceal bleeding in patients with noncirrhotic portal hypertension. Gastroenterology 2010; 139:1238.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/107\" class=\"nounderline abstract_t\">Hirota S, Ichikawa S, Matsumoto S, et al. Interventional radiologic treatment for idiopathic portal hypertension. Cardiovasc Intervent Radiol 1999; 22:311.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/108\" class=\"nounderline abstract_t\">Gane E, Portmann B, Saxena R, et al. Nodular regenerative hyperplasia of the liver graft after liver transplantation. Hepatology 1994; 20:88.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/109\" class=\"nounderline abstract_t\">de Franchis R, Baveno VI Faculty. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol 2015; 63:743.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/110\" class=\"nounderline abstract_t\">Noronha Ferreira C, Seijo S, Plessier A, et al. Natural history and management of esophagogastric varices in chronic noncirrhotic, nontumoral portal vein thrombosis. Hepatology 2016; 63:1640.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/111\" class=\"nounderline abstract_t\">Mathur SK, Shah SR, Nagral SS, Soonawala ZF. Transabdominal extensive esophagogastric devascularization with gastroesophageal stapling for management of noncirrhotic portal hypertension: long-term results. World J Surg 1999; 23:1168.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/112\" class=\"nounderline abstract_t\">Pal S, Radhakrishna P, Sahni P, et al. Prophylactic surgery in non-cirrhotic portal fibrosis:is it worthwhile? Indian J Gastroenterol 2005; 24:239.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/113\" class=\"nounderline abstract_t\">Karagul S, Yagci MA, Tardu A, et al. Portosystemic Shunt Surgery in Patients with Idiopathic Noncirrhotic Portal Hypertension. Ann Transplant 2016; 21:317.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/114\" class=\"nounderline abstract_t\">Bissonnette J, Garcia-Pag&aacute;n JC, Albillos A, et al. Role of the transjugular intrahepatic portosystemic shunt in the management of severe complications of portal hypertension in idiopathic noncirrhotic portal hypertension. Hepatology 2016; 64:224.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/115\" class=\"nounderline abstract_t\">Doki N, Irisawa H, Takada S, et al. Transjugular intrahepatic portosystemic shunt for the treatment of portal hypertension due to idiopathic myelofibrosis. Intern Med 2007; 46:187.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/116\" class=\"nounderline abstract_t\">Bernard PH, Le Bail B, Cransac M, et al. Progression from idiopathic portal hypertension to incomplete septal cirrhosis with liver failure requiring liver transplantation. J Hepatol 1995; 22:495.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/117\" class=\"nounderline abstract_t\">Isabel Fiel M, Thung SN, Hytiroglou P, et al. Liver failure and need for liver transplantation in patients with advanced hepatoportal sclerosis. Am J Surg Pathol 2007; 31:607.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/118\" class=\"nounderline abstract_t\">Isobe Y, Yamasaki T, Yokoyama Y, et al. Hepatocellular carcinoma developing six and a half years after a diagnosis of idiopathic portal hypertension. J Gastroenterol 2007; 42:407.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/119\" class=\"nounderline abstract_t\">Hidaka H, Ohbu M, Kokubu S, et al. Hepatocellular carcinoma associated with idiopathic portal hypertension: review of large nodules in seven non-cirrhotic portal hypertensive livers. J Gastroenterol Hepatol 2005; 20:493.</a></li><li><a href=\"https://www.uptodate.com/contents/noncirrhotic-portal-hypertension/abstract/120\" class=\"nounderline abstract_t\">Schouten JN, Nevens F, Hansen B, et al. Idiopathic noncirrhotic portal hypertension is associated with poor survival: results of a long-term cohort study. Aliment Pharmacol Ther 2012; 35:1424.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 3580 Version 25.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H27\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H64319454\" id=\"outline-link-H64319454\">ETIOLOGY</a><ul><li><a href=\"#H64319853\" id=\"outline-link-H64319853\">Prehepatic and posthepatic causes</a></li><li><a href=\"#H64319860\" id=\"outline-link-H64319860\">Intrahepatic causes</a><ul><li><a href=\"#H64319867\" id=\"outline-link-H64319867\">- Presinusoidal causes</a></li><li><a href=\"#H64319886\" id=\"outline-link-H64319886\">- Sinusoidal causes</a></li><li><a href=\"#H64319893\" id=\"outline-link-H64319893\">- Postsinusoidal causes</a></li></ul></li></ul></li><li><a href=\"#H64323358\" id=\"outline-link-H64323358\">SCHISTOSOMIASIS</a><ul><li><a href=\"#H64323364\" id=\"outline-link-H64323364\">Pathophysiology</a></li><li><a href=\"#H64323370\" id=\"outline-link-H64323370\">Clinical features</a></li><li><a href=\"#H64323394\" id=\"outline-link-H64323394\">Diagnosis</a></li><li><a href=\"#H64323400\" id=\"outline-link-H64323400\">Management</a></li></ul></li><li><a href=\"#H2\" id=\"outline-link-H2\">IDIOPATHIC NONCIRRHOTIC PORTAL HYPERTENSION (INCLUDING NODULAR REGENERATIVE HYPERPLASIA)</a><ul><li><a href=\"#H64320103\" id=\"outline-link-H64320103\">Terminology</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">Epidemiology</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">Pathophysiology</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">Clinical manifestations</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">Diagnosis</a><ul><li><a href=\"#H64321128\" id=\"outline-link-H64321128\">- Diagnostic approach</a></li><li><a href=\"#H165946062\" id=\"outline-link-H165946062\">- Laboratory tests</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">- Imaging</a></li><li><a href=\"#H625703682\" id=\"outline-link-H625703682\">- Liver stiffness</a></li><li><a href=\"#H15\" id=\"outline-link-H15\">- Liver pathology</a></li><li><a href=\"#H16\" id=\"outline-link-H16\">- Hemodynamics</a></li></ul></li><li><a href=\"#H64320430\" id=\"outline-link-H64320430\">Differential diagnosis</a></li><li><a href=\"#H18\" id=\"outline-link-H18\">Management</a><ul><li><a href=\"#H1543171122\" id=\"outline-link-H1543171122\">- Non-selective beta blockers and endoscopic variceal ligation</a></li><li><a href=\"#H4061179689\" id=\"outline-link-H4061179689\">- Portosystemic shunt surgery</a></li><li><a href=\"#H1854138629\" id=\"outline-link-H1854138629\">- Transjugular intrahepatic portosystemic shunt (TIPS)</a></li><li><a href=\"#H568848246\" id=\"outline-link-H568848246\">- Other interventions</a></li></ul></li><li><a href=\"#H21\" id=\"outline-link-H21\">Prognosis</a></li></ul></li><li><a href=\"#H2251068476\" id=\"outline-link-H2251068476\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H27\" id=\"outline-link-H27\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"GAST/3580|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=ID/90007\" class=\"graphic graphic_figure\">- Schistosomiasis life cycle</a></li></ul></li><li><div id=\"GAST/3580|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=ID/58729\" class=\"graphic graphic_picture\">- Stool ova and parasites</a></li><li><a href=\"image.htm?imageKey=NEPH/88449\" class=\"graphic graphic_picture\">- Calcified schistosomal ova in a rectal biopsy</a></li><li><a href=\"image.htm?imageKey=GAST/63404\" class=\"graphic graphic_picture\">- IPH portal tract fibrosis</a></li><li><a href=\"image.htm?imageKey=GAST/51618\" class=\"graphic graphic_picture\">- IPH dilatation portal vein</a></li></ul></li><li><div id=\"GAST/3580|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=GAST/76516\" class=\"graphic graphic_table\">- Classification NCPH</a></li><li><a href=\"image.htm?imageKey=GAST/50663\" class=\"graphic graphic_table\">- Disorders assoc with idiopathic noncirrhotic portal HTN</a></li><li><a href=\"image.htm?imageKey=GAST/80624\" class=\"graphic graphic_table\">- Histologic idiopathic HTN</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=acute-fatty-liver-of-pregnancy\" class=\"medical medical_review\">Acute fatty liver of pregnancy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=acute-portal-vein-thrombosis-in-adults-clinical-manifestations-diagnosis-and-management\" class=\"medical medical_review\">Acute portal vein thrombosis in adults: Clinical manifestations, diagnosis, and management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=amiodarone-monitoring-and-management-of-side-effects\" class=\"medical medical_review\">Amiodarone: Monitoring and management of side effects</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-liver-biopsy\" class=\"medical medical_review\">Approach to liver biopsy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-the-adult-with-splenomegaly-and-other-splenic-disorders\" class=\"medical medical_review\">Approach to the adult with splenomegaly and other splenic disorders</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-the-patient-with-suspected-iron-overload\" class=\"medical medical_review\">Approach to the patient with suspected iron overload</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=autoimmune-hepatitis-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Autoimmune hepatitis: Clinical manifestations and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=budd-chiari-syndrome-epidemiology-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Budd-Chiari syndrome: Epidemiology, clinical manifestations, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=chronic-portal-vein-thrombosis-in-adults-clinical-manifestations-diagnosis-and-management\" class=\"medical medical_review\">Chronic portal vein thrombosis in adults: Clinical manifestations, diagnosis, and management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cirrhosis-in-adults-overview-of-complications-general-management-and-prognosis\" class=\"medical medical_review\">Cirrhosis in adults: Overview of complications, general management, and prognosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-alcoholic-fatty-liver-disease-and-alcoholic-cirrhosis\" class=\"medical medical_review\">Clinical manifestations and diagnosis of alcoholic fatty liver disease and alcoholic cirrhosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-pulmonary-sarcoidosis\" class=\"medical medical_review\">Clinical manifestations and diagnosis of pulmonary sarcoidosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-diagnosis-and-prognosis-of-primary-biliary-cholangitis-primary-biliary-cirrhosis\" class=\"medical medical_review\">Clinical manifestations, diagnosis, and prognosis of primary biliary cholangitis (primary biliary cirrhosis)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=constrictive-pericarditis\" class=\"medical medical_review\">Constrictive pericarditis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=definition-and-classification-of-the-cardiomyopathies\" class=\"medical medical_review\">Definition and classification of the cardiomyopathies</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-and-evaluation-of-chronic-hepatitis-c-virus-infection\" class=\"medical medical_review\">Diagnosis and evaluation of chronic hepatitis C virus infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-and-management-of-cystic-lesions-of-the-liver\" class=\"medical medical_review\">Diagnosis and management of cystic lesions of the liver</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-of-hepatic-sinusoidal-obstruction-syndrome-veno-occlusive-disease-following-hematopoietic-cell-transplantation\" class=\"medical medical_review\">Diagnosis of hepatic sinusoidal obstruction syndrome (veno-occlusive disease) following hematopoietic cell transplantation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-of-schistosomiasis\" class=\"medical medical_review\">Diagnosis of schistosomiasis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=drug-induced-liver-injury\" class=\"medical medical_review\">Drug-induced liver injury</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-clinical-features-and-diagnosis-of-nonalcoholic-fatty-liver-disease-in-adults\" class=\"medical medical_review\">Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-pathogenesis-and-clinical-manifestations-of-schistosomiasis\" class=\"medical medical_review\">Epidemiology, pathogenesis, and clinical manifestations of schistosomiasis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=evaluating-adult-patients-with-established-venous-thromboembolism-for-acquired-and-inherited-risk-factors\" class=\"medical medical_review\">Evaluating adult patients with established venous thromboembolism for acquired and inherited risk factors</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=extrarenal-manifestations-of-autosomal-dominant-polycystic-kidney-disease\" class=\"medical medical_review\">Extrarenal manifestations of autosomal dominant polycystic kidney disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=general-principles-of-the-management-of-variceal-hemorrhage\" class=\"medical medical_review\">General principles of the management of variceal hemorrhage</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hepatic-granulomas\" class=\"medical medical_review\">Hepatic granulomas</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hepatitis-b-virus-screening-and-diagnosis\" class=\"medical medical_review\">Hepatitis B virus: Screening and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hepatotoxicity-associated-with-chronic-low-dose-methotrexate-for-nonmalignant-disease\" class=\"medical medical_review\">Hepatotoxicity associated with chronic low-dose methotrexate for nonmalignant disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=methods-to-achieve-hemostasis-in-patients-with-acute-variceal-hemorrhage\" class=\"medical medical_review\">Methods to achieve hemostasis in patients with acute variceal hemorrhage</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=noninvasive-assessment-of-hepatic-fibrosis-ultrasound-based-elastography\" class=\"medical medical_review\">Noninvasive assessment of hepatic fibrosis: Ultrasound-based elastography</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-the-myeloproliferative-neoplasms\" class=\"medical medical_review\">Overview of the myeloproliferative neoplasms</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=portal-hypertension-in-adults\" class=\"medical medical_review\">Portal hypertension in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=prevention-of-recurrent-variceal-hemorrhage-in-patients-with-cirrhosis\" class=\"medical medical_review\">Prevention of recurrent variceal hemorrhage in patients with cirrhosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=primary-and-pre-primary-prophylaxis-against-variceal-hemorrhage-in-patients-with-cirrhosis\" class=\"medical medical_review\">Primary and pre-primary prophylaxis against variceal hemorrhage in patients with cirrhosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=primary-sclerosing-cholangitis-in-adults-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Primary sclerosing cholangitis in adults: Clinical manifestations and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=role-of-transjugular-intrahepatic-portosystemic-shunts-in-the-treatment-of-variceal-bleeding\" class=\"medical medical_review\">Role of transjugular intrahepatic portosystemic shunts in the treatment of variceal bleeding</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-portal-hypertension-and-ascites\" class=\"medical medical_society_guidelines\">Society guideline links: Portal hypertension and ascites</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-and-prevention-of-schistosomiasis\" class=\"medical medical_review\">Treatment and prevention of schistosomiasis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=wilson-disease-clinical-manifestations-diagnosis-and-natural-history\" class=\"medical medical_review\">Wilson disease: Clinical manifestations, diagnosis, and natural history</a></li></ul></div></div>","javascript":null}